Jazz Pharmaceuticals (NASDAQ:JAZZ) Given Buy Rating at Barclays

Barclays reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. Barclays currently has a $182.00 target price on the specialty pharmaceutical company’s stock.

A number of other research analysts have also weighed in on the company. BidaskClub lowered Jazz Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, October 11th. TheStreet lowered Jazz Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, October 18th. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. Evercore ISI reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Monday, August 12th. Finally, Zacks Investment Research lowered Jazz Pharmaceuticals from a buy rating to a hold rating and set a $138.00 target price on the stock. in a report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $165.71.

JAZZ traded up $4.18 during midday trading on Thursday, reaching $130.14. 747,500 shares of the company were exchanged, compared to its average volume of 551,936. The stock has a market capitalization of $7.24 billion, a P/E ratio of 10.63, a PEG ratio of 1.57 and a beta of 1.09. Jazz Pharmaceuticals has a one year low of $113.52 and a one year high of $154.44. The stock’s 50-day simple moving average is $124.77 and its 200 day simple moving average is $131.70. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.91. The firm had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a return on equity of 28.57% and a net margin of 29.61%. The business’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.58 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals will post 13.54 earnings per share for the current year.

In related news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the sale, the chief executive officer now directly owns 311,855 shares in the company, valued at approximately $40,541,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Insiders have sold a total of 5,371 shares of company stock worth $730,575 over the last three months. 4.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MUFG Americas Holdings Corp bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $29,000. Condor Capital Management boosted its stake in Jazz Pharmaceuticals by 3.1% in the 3rd quarter. Condor Capital Management now owns 10,414 shares of the specialty pharmaceutical company’s stock valued at $1,334,000 after purchasing an additional 318 shares during the period. Systematic Financial Management LP boosted its stake in Jazz Pharmaceuticals by 0.8% in the 3rd quarter. Systematic Financial Management LP now owns 106,278 shares of the specialty pharmaceutical company’s stock valued at $13,618,000 after purchasing an additional 794 shares during the period. Balasa Dinverno & Foltz LLC bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $408,000. Finally, Means Investment CO. Inc. boosted its stake in Jazz Pharmaceuticals by 25.6% in the 3rd quarter. Means Investment CO. Inc. now owns 3,190 shares of the specialty pharmaceutical company’s stock valued at $410,000 after purchasing an additional 650 shares during the period. Institutional investors and hedge funds own 87.71% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is meant by holder of record?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.